癌组织M6A甲基转移酶样蛋白3水平对手术切除后接受索拉非尼治疗的肝细胞癌患者预后的影响*

doi:10.3969/j.issn.1672-5069.2022.06.032

摘要/Abstract

摘要： 目的探讨肝细胞癌(HCC)组织N⁶-甲基嘌呤(M6A)甲基转移酶样蛋白3(METTL3)水平及其对术后索拉非尼治疗的患者预后的预测价值。方法 2016年8月～2019年8月我院手术切除治疗的HCC患者62例,随访2年。采用qRT-PCR法检测癌组织和癌旁组织METTL3 mRNA水平,应用受试者工作特征曲线(ROC)下面积(AUC)分析癌组织METTL3 mRNA水平对患者预后的预测价值。结果癌组织METTL3 mRNA水平为(7.7±1.4),显著高于癌旁组织【(5.3±1.1),P＜0.05】;肿瘤直径≥5 cm、TNM Ⅲ期和肝外转移患者癌组织METTL3 mRNA水平分别为(8.1±1.1)、(8.2±1.4)和(8.6±0.8),显著高于肿瘤直径＜5 cm、TNM Ⅰ/Ⅱ期和无肝外转移患者【分别为(7.0±0.9)、(7.3±0.7)和(7.4±1.2),P＜0.05】;在随访2年末,HCC患者生存27例,死亡35例;生存组癌组织METTL3 mRNA水平为(7.0±1.0),显著低于死亡组【(8.2±1.1),P＜0.05】;以METTL3 mRNA水平为7.6为最佳截断点,预测患者死亡的AUC为0.712【95%CI(0.584～00.839)】,其灵敏度、特异度和准确度分别为71.4%、66.7%和69.4%;癌组织METTL3 mRNA低水平组2 a总体生存率为64.3%,显著高于高水平组的26.5%(P＜0.05)。结论肝细胞癌患者癌组织METTL3 mRNA呈现高水平,且其高水平状态与肿瘤直径、TNM分期和肝外转移有关,预示患者不良预后。检测癌组织METTL3 mRNA水平可作为手术切除接受索拉非尼治疗的HCC患者的预后指标。

关键词: 肝细胞癌, 索拉非尼, N⁶-甲基嘌呤, 甲基转移酶样蛋白3, 预后

Abstract: Objective This study was to explore the prognosis of patients with hepatocellular carcinoma (HCC) after hepatectomy and sorafenib therapy by cancerous N⁶-methylpurine (M6A) methyltransferase-like protein 3 (METTL3) levels. Methods A total of 62 patients with HCC were enrolled in our hospital between August 2016 and August 2019, and all patients underwent hepatectomy, receiving sorafenib therapy after operation and followed-up for two years. The cancerous and non-cancerous tissue METL3 mRNA levels were detected by qRT-PCR. The prognostic value of cancerous METL3 mRNA was analyzed by area under the receiver operating characteristic (ROC) curves (AUC). Results The cancerous METL3 mRNA level was significantly higher than that in adjacent tissues [(7.7±1.4) vs. (5.3±1.1), P<0.05]; the cancerous METL3 mRNA levels in patients with tumor diameter ≥5 cm, TNM stage Ⅲ and with extrahepatic metastasis were (8.1±1.1), (8.2±1.4)and (8.6±0.8), all significantly higher than [(7.0±0.9), (7.3±0.7)and (7.4±1.2), P<0.05] in patients with tumor diameter <5 cm, TNM staging stage Ⅰ-Ⅱ and without extrahepatic metastasis (P＜0.05); at the end of two-year follow-up, 27 patients survived and 35 died; the cancerous METTL3 mRNA level in survived patients was (7.0±1.0), significantly lower than [(8.2±1.1), P＜0.05] in died ones; the AUC was 0.712 [95%CI(0.584-00.839)] when the optimal cut-off-value of cancerous METTL3 mRNA level was set at 7.6, with the sensitivity, specificity and accuracy of 71.4%, 66.7% and 69.4%; the total survival in patients with lower cancerous METTL3 mRNA levels was 64.3%, significantly higher than 26.5%(P＜0.05) in those with high cancerous METTL3 mRNA levels. Conclusion The cancerous METTL3 mRNA levels in patients with HCC is up-regulated, and the cancerous METTL3 mRNA level is correlated to tumor diameter, TNM staging and extrahepatic metastasis. The surveillance of cancerous METTL3 mRNA levels might help predict the prognosis of HCC patients receiving sorafenib therapy after hepatectomy.

Key words: Hepatocellular carcinoma, Hepatectomy, Sorafenib, N⁶-methylpurine, Methyltransferase-like protein 3, Prognosis

高正兴, 李广欣, 宋春青. 癌组织M6A甲基转移酶样蛋白3水平对手术切除后接受索拉非尼治疗的肝细胞癌患者预后的影响^*[J]. 实用肝脏病杂志, 2022, 25(6): 885-888.

Gao Zhengxing, Li Guangxin, Song Chunqing. Prognosis of patients with hepatocellular carcinoma after hepatectomy and sorafenib therapy: prediction by cancerous M6A methyltransferase-like protein 3 levels[J]. Journal of Practical Hepatology, 2022, 25(6): 885-888.

参考文献

[1] 陈静,余君铭,刘腾飞,等.沉默EFNA3基因水平抑制缺氧诱导的肝细胞癌细胞的迁移与侵袭.肿瘤,2020,327(5):7-18.
[2] Perfahl H, Jain HV, Joshi T, et al. Hybridmodelling of transarterial chemoembolisation therapies (TACE) for hepatocellular carcinoma (HCC). Sci Rep, 2020,10(1):10571.
[3] Raghav K, Lee RT , Paluri RK, et al. An open-label phase Ib/2 trial of TRC105 plus sorafenib in patients with advanced/metastatic hepatocellular carcinoma (HCC) . J Clin Oncol,2019, 37(4):268.
[4] Wu Z, Shi Y, Lu M, et al. METTL3 counteracts premature aging via m6A-dependent stabilization of MIS12 mRNA. Nucl Acid Res, 2020,48(19):11083-11096.
[5] Wu Y, Chang N, Zhang Y, et al. METTL3-mediated m6A mRNA modification of FBXW7 suppresses lung adenocarcinoma. J Exp Clin Cancer Res, 2021,40(1):90.
[6] Qin Y, Qiao Y, Li L, et al. The m6A methyltransferase METTL3 promotes hypoxic pulmonary arterial hypertension. Life Sci, 2021, 274(10):119366.
[7] Dahal U, Kang L, Gupta M. RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2. Melanoma Res, 2019,8(1):65-69.
[8] Wu H, Li F, Zhu R. miR-338-5p inhibits cell growth and migration via inhibition of the METTL3/m6A/c-Myc pathway in lung cancer. Acta Bioch Bioph Sin, 2020,53(3):304-316.
[9] Tzelepis K, Braekeleer ED, YankovaE, et al. Pharmacological inhibition of the RNA m6a writer METTL3 as a novel therapeutic strategy for acute myeloid leukemia. Blood, 2019,134(1):403-405.
[10] 李显永,官润云,柯坤彬,等.甲基转移酶3在前列腺癌中的水平及其临床意义.实用医学杂志, 2019,35(1):75-79.
[11] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版).临床肿瘤学杂志, 2011,16(10):71-88.
[12] 王虎明,樊东升,徐杰,等.肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨.实用肝脏病杂志,2019,22(2):248-251.
[13] Jiang H, Ning G, Wang Y, et al. Identification of an m6A-related signature as biomarker for hepatocellular carcinoma prognosis and correlates with sorafenib and anti-PD-1 immunotherapy treatment response. Dis Markers, 2021,24(3):1-15.
[14] Cao Z, Zhang L, Hong R,et al. METTL3-mediated m6A methylation negatively modulates autophagy to support porcine blastocyst development. Biol Reprod,2021,104(5):22-24.
[15] Liu S, Li Q, Li G, et al. The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene. Cell Death Dis, 2020,11(11):969.
[16] Hong WA, Bei XB, Js C. N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.Gene, 2020,722(5):144-146.
[17] Lubbock A, Stewart GD, Mahony FC. Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer. BMC Med, 2017,15(1):118-127.
[18] Yao MD, Jiang Q, Ma Y, et al. Role of METTL3-dependent N6-methyladenosine mRNA modification in the promotion of angiogenesis. Mol Ther, 2020,28(10):2191-2202.
[19] ChengC, Wu Y, Xiao T, et al. METTL3-mediated m6A modification of ZBTB4 mRNA is involved in the smoking-induced EMT in cancer of the lung - science direct. Mol Ther Nucl Acid, 2021,23(5):487-500.
[20] 方义杰, 潘洁琳, 卢慧芳,等. 应用肿瘤三维体积测量早期评估肝细胞癌索拉非尼靶向治疗疗效的可行性及可重复性. 中华放射学杂志, 2019,53(2):133-137.

癌组织M6A甲基转移酶样蛋白3水平对手术切除后接受索拉非尼治疗的肝细胞癌患者预后的影响^*

Prognosis of patients with hepatocellular carcinoma after hepatectomy and sorafenib therapy: prediction by cancerous M6A methyltransferase-like protein 3 levels

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	贺潇瑾, 李丹, 周青, 欧阳静, 田玉球, 谭英征. L02细胞乙型肝炎病毒X蛋白和SOCS-1基因水平研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 772-775.
[2]	李荣, 曹晶晶, 李晶, 潘峰. 慢加急性/亚急性乙型肝炎肝衰竭患者发病诱因及影响临床转归因素分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 832-835.
[3]	沈亦亮, 沈冬元, 陈永莹, 江凯, 朱逸明, 葛尚. 肝硬化患者肝内LR-3类结节恶变风险评估及预测模型的建立^*[J]. 实用肝脏病杂志, 2022, 25(6): 836-839.
[4]	朱海艳, 范晓棠. 肝硬化并发门静脉血栓形成患者列线图预测模型分析及外部验证[J]. 实用肝脏病杂志, 2022, 25(6): 848-852.
[5]	张耀辉, 郑章增, 高星, 张亚利. 超声造影时间-强度曲线诊断肝硬化患者肝内小结节病灶价值研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 861-864.
[6]	石青春, 潘立民, 布凡, 王永强, 关睿骞. 基于TCGA研究细胞坏死相关基因对肝细胞癌患者预后的影响^*[J]. 实用肝脏病杂志, 2022, 25(6): 869-872.
[7]	郑希彦, 杜飞, 林志群, 李瑞曦, 周正, 张广权, 周红, 何方平, 史宪杰. 肝细胞癌进展:代谢综合征相关危险因素研究[J]. 实用肝脏病杂志, 2022, 25(6): 877-880.
[8]	崔坡, 董士铭, 南月敏. 慢性基础肝病对新型冠状病毒肺炎患者结局的影响^*[J]. 实用肝脏病杂志, 2022, 25(6): 905-908.
[9]	王倩, 李文莉, 王兵, 吴茂盛, 魏芳芳. 70例登革热并发肝损伤患者临床特征和预后因素分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 645-648.
[10]	刘艳, 沈宇, 张茜. 60例药物性肝损伤患者临床特征和转归分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 649-652.
[11]	王明强, 牛垚飞, 王生锋. 慢加急性乙型肝炎肝衰竭患者血清聚集素水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(5): 677-680.
[12]	吴桐, 张巧丽, 齐雪维. 肝细胞癌RNA结合蛋白功能和预后价值系统分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 693-697.
[13]	杜联江, 李京涛, 崔杰. 肝细胞癌癌组织caspase-3和DcR3蛋白及SNHG12 mRNA水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(5): 706-709.
[14]	李清汉, 甄作均, 何尹韬. 肝动脉化疗栓塞联合射频消融和免疫靶向治疗术后复发的肝细胞癌患者近远期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 714-717.
[15]	施莹, 柏根基, 孙阳. 多模态MRI对肝硬化增生性结节与小肝癌的鉴别诊断价值探讨^*[J]. 实用肝脏病杂志, 2022, 25(5): 722-725.